This site use cookies
This site uses cookies that help us to improve our site by providing analytics and usage information. By clicking accept or continuing to use this site you are agreeing to our cookie policy. If you do not agree, please close this notice. Learn more

Exonate at Biotrinity 2021

Posted on 21 Jun 2021

Fully hybrid partnering and investment conference for the lifesciences industry– 21st– 25th June

Cambridge, UK, 21st June 2021 Exonate is pleased to attend BioTrinity a highly regarded biopartnering & investment life sciences conference, that aims to shine a light on new innovation in the life sciences industry and inspire growth and create opportunities for all who attend.

The 2021 event will be delivered in a true hybrid format, and will provide seamless LIVE interaction for delegates, who include early-stage and emerging biotech, medtech and digital health companies, big pharma executives, life sciences investors and service providers.
 Dr. Catherine Beech, CEO and members of Exonate’s management team are available for meetings and contact can be made via Sarah Buchallet.




Exonate Limited

Sarah Buchallet, Marketing

Catherine Beech, CEO Tel:  +44 (0) 1223 734710



About Exonate:

Exonate are using the mRNA blueprint as a therapeutic formula to instruct cells in how to treat diseases. Leveraging our expertise in the alternative mRNA splicing of Vascular Endothelial Growth Factor (VEGF) we have developed a pipeline of small molecule drugs for the treatment of patients with chronic diseases

Exonate’s lead compound, formulated to be delivered topically with eye drops, is now in Phase 1 clinical trials for the treatment of centre-involved diabetic macular oedema. The clinical trial is in collaboration with Janssen Pharmaceuticals, Inc., and built upon extensive pre-clinical work supported by previous investments. Having relocated to larger research labs at MediCity we are continuing our pre-clinical mRNA-targeting research focusing on ophthalmology and renal disease. 


Categories related to this article

Company news